申请人:Pinney G. Kevin
公开号:US20060293394A1
公开(公告)日:2006-12-28
Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.
已经发现了与康柏他斯汀类似的化合物,它们展示出令人印象深刻的细胞毒性,以及抑制微管聚合的显著能力。这些化合物是治疗人类癌症的优秀临床候选药物。此外,这些配体中的某些作为前药,很可能证明是肿瘤选择性血管靶向化疗药物,或具有血管靶向活性,导致选择性预防和/或破坏非恶性增殖的血管。